These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10577980)

  • 1. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
    Fries JF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I86-9. PubMed ID: 10577980
    [No Abstract]   [Full Text] [Related]  

  • 2. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    Modena V; Bianchi G; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 6. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological disease modifying anti-rheumatic drugs.
    Cranwell-Bruce LA
    Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of long-term treatment of rheumatoid arthritis.
    Blumenauer B; Coyle D; Tugwell P
    Expert Opin Pharmacother; 2002 Apr; 3(4):417-22. PubMed ID: 11934345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis.
    Sutor SM; Gricar JA; Cave DG
    Manag Care Interface; 1999 Jun; 12(6):51-3. PubMed ID: 10538460
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
    Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of anti-tumor necrosis factor agents.
    Wong JB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S65-70. PubMed ID: 15552517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
    Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
    Nurmohamed MT; Dijkmans BA
    Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.